Is Medico Remedies overvalued or undervalued?

Current Valuation Metrics and Market Performance

As of 27 Nov 2025, Medico Remedies trades at a price of ₹51.00, slightly up from the previous close of ₹49.86. The stock has experienced a 52-week price range between ₹35.00 and ₹79.78, indicating significant volatility over the past year. Despite a modest weekly return of 0.1%, the stock has outperformed the Sensex over the past month with a 4.27% gain compared to the benchmark’s 1.11%. However, year-to-date returns remain negative at -6.3%, contrasting with the Sensex’s positive 9.7%.

Longer-term performance shows a mixed picture. While the stock has delivered an impressive 1258.19% return over five years, it has underperformed the Sensex over three years, with a negative 10.16% return versus the Sensex’s 37.61%. This suggests that while Medico Remedies has had periods of strong growth, recent years have been challenging relative to the broader market.

Valuation Ratios Indicate Elevated Pricing

Medico Remedies’ price-to-earnings (PE) ratio stands at 37.29, which is considerably higher than many of its pharmaceutical peers. The price-to-book (P/B) ratio is 6.33, signalling that the stock is trading at a premium to its net asset value. Enterprise value to EBIT (EV/EBIT) and EV to EBITDA ratios are 35.28 and 28.31 respectively, both indicating a relatively expensive valuation compared to typical industry standards.

Interestingly, the company’s PEG ratio is 0.78, which is below 1.0, suggesting that the stock’s price growth is not excessively high relative to its earnings growth potential. This metric often points to undervaluation, but in this case, it contrasts with other valuation indicators, signalling a nuanced picture.

Comparative Peer Analysis

When compared with its pharmaceutical peers, Medico Remedies is classified as expensive but not excessively so. For instance, Sun Pharma Industries also carries an expensive valuation with a PE ratio slightly above Medico Remedies, but a much higher PEG ratio, indicating slower earnings growth expectations. On the other hand, companies like Divi’s Laboratories and Torrent Pharma are rated very expensive, with PE ratios well above 50 and EV/EBITDA multiples exceeding 30, reflecting their premium market positioning.

Conversely, several large-cap peers such as Cipla, Dr Reddy’s Laboratories, and Zydus Lifesciences are considered attractive investments based on their lower PE and EV/EBITDA ratios. These companies trade at more reasonable valuations, suggesting that Medico Remedies is priced at a premium relative to these benchmarks.

Profitability and Return Metrics Support Valuation

Medico Remedies’ return on capital employed (ROCE) is 15.85%, and return on equity (ROE) stands at 16.98%. These figures indicate solid profitability and efficient capital utilisation, which justify a higher valuation to some extent. However, the absence of a dividend yield may deter income-focused investors, placing greater emphasis on capital appreciation potential.

The company’s EV to capital employed ratio of 5.59 and EV to sales ratio of 2.53 further reflect a premium valuation, but these are not outliers within the sector. Investors appear to be pricing in growth prospects and operational efficiency, but the elevated multiples suggest limited margin for valuation expansion.

Conclusion: Valuation Verdict

Medico Remedies’ recent upgrade from a fair to an expensive valuation grade reflects the market’s recognition of its growth potential and profitability metrics. However, the elevated PE and EV multiples relative to many peers indicate that the stock is currently priced at a premium. While the PEG ratio below 1.0 suggests some earnings growth justification, the overall valuation appears stretched when compared to more attractively priced competitors.

Investors should weigh the company’s strong five-year returns and solid profitability against its recent underperformance relative to the Sensex and the premium valuation multiples. For those seeking growth exposure in the pharmaceutical sector, Medico Remedies offers potential but with limited margin of safety. More value-conscious investors might consider peers with lower valuations and comparable fundamentals.

In summary, Medico Remedies is currently overvalued relative to its sector and historical benchmarks, though not excessively so. Careful monitoring of earnings growth and market conditions will be essential for investors considering this stock as part of their portfolio.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →